Medarex Announces Initiation Of Phase 2 Clinical Trials For The Treatment Of Ulcerative Colitis And Rheumatoid Arthritis

Medarex, Inc. (Nasdaq: MEDX) announced that it has initiated the Phase 2 clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10 (also known as IP-10), in ulcerative colitis (UC) and rheumatoid arthritis (RA). MDX-1100 could potentially treat UC and RA by suppressing the inflammatory process characteristic of these diseases.

More: continued here

Filed under: Arthritis on May 15th, 2008